MiR-297 inhibits tumour progression of liver cancer by targeting PTBP3.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
26 08 2023
26 08 2023
Historique:
received:
12
07
2021
accepted:
21
08
2023
revised:
11
08
2023
medline:
28
8
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Whereas increasing evidences demonstrate that miR-297 contributes to the tumour development and progression, the role of miR-297 and its underlying molecular mechanisms in hepatocellular carcinoma (HCC) was still unclear. Here, we reported that the expression of miR-297 increased significantly in hepG2 cells after the treatment of the conditioned medium of human amniotic epithelial cells(hAECs) which can inhibit the proliferation and migration of hepG2. And the overexpression of miR-297 inhibits the cell proliferation, migration and invasion of HCC cell lines in vitro and suppressed the tumorigenesis of HCC in vivo. Polypyrimidine tract-binding protein 3 (PTBP3) was identified as a direct target gene of miR-297 in HCC cell lines, and mediated the function of miR-297 in HCC cells. In clinical samples, miR-297 levels have a tendency to decrease, but there are no statistically significant differences. Furthermore, in vitro cell experiments confirmed that overexpression of miR-297 could inhibit the PI3K/AKT signaling pathway by down-regulating PTBP3 expression, thereby inhibiting the proliferation, migration and invasion of HCC cells. In conclusion, our results revealed that miR-297 could down-regulate the expression of PTBP3 and inhibit the activation of PI3K/AKT signaling pathway, thereby preventing HCC growth, migration and invasion.
Identifiants
pubmed: 37633911
doi: 10.1038/s41419-023-06097-0
pii: 10.1038/s41419-023-06097-0
pmc: PMC10460384
doi:
Substances chimiques
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
MicroRNAs
0
PTBP3 protein, human
0
Polypyrimidine Tract-Binding Protein
139076-35-0
MIRN297 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
564Informations de copyright
© 2023. The Author(s).
Références
Br J Cancer. 2017 Mar 28;116(7):903-911
pubmed: 28222070
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochem Biophys Res Commun. 2015 Jul 31;463(3):315-21
pubmed: 26022123
Mol Cell. 2012 Dec 14;48(5):771-84
pubmed: 23123196
J Exp Med. 2013 Apr 8;210(4):789-803
pubmed: 23478189
Int J Mol Sci. 2020 Oct 19;21(20):
pubmed: 33086620
Front Pharmacol. 2022 Mar 10;13:811338
pubmed: 35359851
Neuro Oncol. 2013 Dec;15(12):1652-63
pubmed: 24158111
Stem Cell Res Ther. 2015 Aug 25;6:152
pubmed: 26303743
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cytotherapy. 2014 Jan;16(1):33-40
pubmed: 24113429
Oncogene. 2007 Jul 26;26(34):4961-8
pubmed: 17310993
Cancer Res. 2018 Jan 15;78(2):387-398
pubmed: 29187406
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Int J Mol Sci. 2017 Jan 17;18(1):
pubmed: 28106737
Nat Rev Genet. 2010 Sep;11(9):597-610
pubmed: 20661255
Nature. 2012 Feb 15;482(7385):347-55
pubmed: 22337054
CA Cancer J Clin. 2012 Nov-Dec;62(6):394-9
pubmed: 23070690
Oncogene. 2010 May 13;29(19):2884-91
pubmed: 20190818
Oncogene. 2012 Jan 26;31(4):432-45
pubmed: 21725369
Oncotarget. 2015 Oct 13;6(31):30818-30
pubmed: 26360780
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2140-51
pubmed: 26284591
Pathol Res Pract. 2020 Jun;216(6):152982
pubmed: 32360250
Cell Cycle. 2022 Jul;21(13):1406-1421
pubmed: 35323096
J Biol Chem. 2008 Jul 18;283(29):20277-87
pubmed: 18499661
Future Oncol. 2011 Oct;7(10):1149-67
pubmed: 21992728
Life Sci. 2014 Sep 26;114(1):29-35
pubmed: 25119103
Biochem J. 2012 Sep 1;446(2):291-300
pubmed: 22676135
Cell Prolif. 2016 Oct;49(5):636-43
pubmed: 27554041
World J Hepatol. 2015 Jul 28;7(15):1964-70
pubmed: 26244070